about
Inhibition of firefly luciferase by general anesthetics: effect on in vitro and in vivo bioluminescence imagingHIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.Bioluminescence imaging: looking beyond the light.Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy.Plasma protein binding of luciferase substrates influences sensitivity and accuracy of bioluminescence imaging.Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D: -luciferin: effect on intensity, time kinetics and repeatability of photon emission.Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery.Adjuvant-Enhanced mRNA Vaccines.Genome-wide computational analysis reveals cardiomyocyte-specific transcriptional Cis-regulatory motifs that enable efficient cardiac gene therapyPreliminary in vivo evaluation of [131I]-2-iodo-D-phenylalanine as a potential radionuclide therapeutic agent in R1M-fluc rhabdomyosarcoma tumor-bearing NuNu mice using bioluminescent imaging.Regional quantitative analysis of small animal myocardial sympathetic innervation and initial application in streptozotocin induced diabetes.123I-2-iodo-tyrosine, a new tumour imaging agent: human biodistribution, dosimetry and initial clinical evaluation in glioma patients.Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.Air leaks localized with lung ventilation SPECT.A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches.Next-generation muscle-directed gene therapy by in silico vector designIntra-individual comparison of the human biodistribution and dosimetry of the D and L isomers of 2-[123I]iodo-phenylalanineSelective spleen SPECT/CTAgenesis of the pubic symphysis detected with SPECT-CTSame-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in OncologyNoninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical UseClinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic MacrophagesLabeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo BehaviorSingle Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine ProductionPerforin and Granzyme B Expressed by Murine Myeloid-Derived Suppressor Cells: A Study on Their Role in Outgrowth of Cancer CellsEvaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic AgentUndetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapyPreclinical Targeted α- and β--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies
P50
Q27310133-572C26CA-F7C9-4238-B6AB-7BA3323DDC8FQ33877397-EF4C7F17-F240-4C26-BE7E-75DC7ECEA88FQ36299661-979616F0-240D-4560-AAF4-AD1DF732A8D9Q37085052-6B85D3B3-FF55-4A1B-8C7A-B4D98C2ADB2CQ37982886-8B9D064B-9B36-4350-A68E-F18AF93DB128Q38836740-2C5F5242-DF9E-4DFA-BD7C-7FB70D27FC5DQ39181509-35AC3A55-9EAC-4864-883F-8CA7F1C03451Q39652063-7D45892E-9D53-4049-A074-763A8E35C73CQ39716044-2E22B24D-B3F6-4171-BB77-A631966ED413Q39991878-53389A5C-5875-4186-BA4F-5BB005A9734AQ40027511-75155FCE-477A-4A45-8BC7-4298D3608789Q40187007-6790E3F2-7A29-45BA-95AF-A88E36D10142Q40420219-A296D450-101D-4986-9F7E-A42FE82C9BD0Q40516718-D1B73797-6012-4EC9-A895-72B44BB02FCDQ43084117-7534503F-BA50-4824-BEAC-F455B34C4B9AQ43293514-A7111C64-1B0A-434A-BAF0-C9C5BEF7549DQ48304014-3C203F50-B6A5-4343-A230-CE0F72A32967Q49107699-532E0FB7-5F0B-44E3-9B67-D0550CC291CFQ53140870-7A4648BA-EFD4-4D45-AC16-C01CB808FB97Q55348052-499D7997-07BA-4F40-AC2E-AA9591912F38Q61806384-1BBFC96E-B608-4282-AE44-146869984C87Q80866490-68B6BE7C-2F30-4E67-9E91-75CB873003B6Q83457754-6115A591-8BF8-4824-BB95-D81FB2CCBF37Q84427425-DCE2B6AF-B291-40B0-985B-E2E7EABEEBFBQ88072946-3839248A-A47B-4E01-92E4-28FD7B794D41Q90383028-B39CEC77-1133-4FB4-A8CE-BF48C125BB5DQ91172800-6186A261-E143-4FA9-B3AA-B2304D7F3398Q91579544-30F7C209-8ABD-402C-9CA4-81FC356150F2Q92503738-26DCB70A-409C-4CE8-B6C1-2BD811A72C6FQ92853591-8DF7366A-C5AD-4AAB-B7C9-5BBFDA6F970FQ92990274-D08E0F65-87ED-415A-A538-8E3BB0854AA6Q93129151-D45FD817-7F8C-4BC8-9018-9547C035D631Q93187209-1C7E2FC8-ED18-4343-9FA6-B12ADDA1FEBB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marleen Keyaerts
@ast
Marleen Keyaerts
@en
Marleen Keyaerts
@es
Marleen Keyaerts
@nl
type
label
Marleen Keyaerts
@ast
Marleen Keyaerts
@en
Marleen Keyaerts
@es
Marleen Keyaerts
@nl
prefLabel
Marleen Keyaerts
@ast
Marleen Keyaerts
@en
Marleen Keyaerts
@es
Marleen Keyaerts
@nl
P106
P31
P496
0000-0002-9997-4571